51
|
Pérol M, Quantin X, Lena H, Filleron T, Chouaid C, Valette CA, Kaderbhai C, Chenuc G, Santorelli M, Bensimon L, Burke T, Simon G, Martin AL, Debieuvre D, Gervais R, Schott R, Carton M, Courtinard C, Girard N. 110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01952-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
52
|
McDonald F, Mornex F, Garassino M, Filippi A, Christoph D, Haakensen V, Agbarya A, Van den Heuvel M, Vercauter P, Chouaid C, Pichon E, Siva S, Steinbusch L, Peretz I, Solomon B, Decoster L, Sawyer W, Allen A, Licour M, Girard N. 79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01921-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
53
|
Viteri S, Bauml J, Bazhenova L, Ou SH, Girard N, Schaffer M, Rose J, Curtin J, Karkera J, Mahadevia P, Minchom A. 1P Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01843-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
54
|
Sabari J, Shu C, Park K, Leighl N, Mitchell P, Kim S, Lee J, Kim D, Viteri S, Spira A, Han J, Trigo J, Lee C, Lee K, Girard N, Yang T, Goto K, Sanborn R, Yang J, Xie J, Roshak A, Thayu M, Knoblauch R, Cho B. OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.284] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
55
|
Mangiante L, Alcala N, Di Genova A, Sexton-Oates A, Giacobi C, Le-Stang N, Boyault S, Damiola F, Mesobank M, Lantuejoul S, Caux C, Girard N, Galateau Salle F, Foll M, Fernandez-Cuesta L. OA09.03 MESOMICS Project: Molecular Characterization of Malignant Pleural Mesothelioma Using a Multi-Omic Approach. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
56
|
Girard N, Bazhenova L, Minchom A, Ou S, Gadgeel S, Trigo J, Viteri S, Li G, Mahadevia P, Londhe A, Backenroth D, Li T, Bauml J. MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.228] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
57
|
Couraud S, Ferretti G, Milleron B, Cortot A, Girard N, Gounant V, Laurent F, Leleu O, Quoix E, Revel MP, Wislez M, Westeel V, Zalcman G, Scherpereel A, Khalil A. [Recommendations of French specialists on screening for lung cancer]. Rev Mal Respir 2021; 38:310-325. [PMID: 33637394 DOI: 10.1016/j.rmr.2021.02.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 01/25/2021] [Indexed: 12/17/2022]
|
58
|
Testud B, Brun G, Varoquaux A, Hak JF, Appay R, Le Troter A, Girard N, Stellmann JP. Perfusion-weighted techniques in MRI grading of pediatric cerebral tumors: efficiency of dynamic susceptibility contrast and arterial spin labeling. Neuroradiology 2021; 63:1353-1366. [PMID: 33506349 DOI: 10.1007/s00234-021-02640-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 01/06/2021] [Indexed: 01/23/2023]
Abstract
PURPOSE Dynamic susceptibility contrast (DSC) and arterial spin labeling (ASL) perfusion MRI are applied in pediatric brain tumor grading, but their value for clinical daily practice remains unclear. We explored the ability of ASL and DSC to distinguish low- and high-grade lesions, in an unselected cohort of pediatric cerebral tumors. METHODS We retrospectively compared standard perfusion outcomes including blood volume, blood flow, and time parameters from DSC and ASL at 1.5T or 3T MRI scanners of 46 treatment-naive patients by drawing ROI via consensus by two neuroradiologists on the solid portions of every tumor. The discriminant abilities of perfusion parameters were evaluated by receiver operating characteristic (ROC) over the entire cohort and depending on the tumor location and the magnetic field. RESULTS ASL and DSC parameters showed overall low to moderate performances to distinguish low- and high-grade tumors (area under the curve: between 0.548 and 0.697). Discriminant abilities were better for tumors located supratentorially (AUC between 0.777 and 0.810) than infratentorially, where none of the metrics reached significance. We observed a better differentiation between low- and high-grade cancers at 3T than at 1.5-T. For infratentorial tumors, time parameters from DSC performed better than the commonly used metrics (AUC ≥ 0.8). CONCLUSION DSC and ASL show moderate abilities to distinguish low- and high-grade brain tumors in an unselected cohort. Absolute value of K2, TMAX, tMIP, and normalized value of TMAX of the DSC appear as an alternative to conventional parameters for infratentorial tumors. Three Tesla evaluation should be favored over 1.5-Tesla.
Collapse
|
59
|
André MV, Cacciagli P, Cano A, Vaugier L, Roussel M, Girard N, Chabrol B, Villard L, Milh M. The phenotype caused by recessive variations in SLC25A22: Report of a new case and literature review. Arch Pediatr 2020; 28:87-92. [PMID: 33342683 DOI: 10.1016/j.arcped.2020.10.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 07/20/2020] [Accepted: 10/31/2020] [Indexed: 10/22/2022]
Abstract
We describe the clinical, electroencephalography (EEG), and developmental features of a patient with developmental and epileptic encephalopathy due to a homozygous pathogenic variation of mitochondrial glutamate/H+ symporter SLC25A22. Epilepsy began during the first week of life with focal onset seizures. Interictal EEG revealed a suppression-burst pattern with extensive periods of non-activity. The prospective follow-up confirmed developmental encephalopathy as well as ongoing active epilepsy and almost no sign of development at 8 years of age. We confirm in the following paper that SLC25A22 recessive variations may cause a severe developmental and epileptic encephalopathy characterized by a suppression-burst pattern. On the basis of an in-depth literature review, we also provide an overview of this rare genetic cause of neonatal onset epilepsy.
Collapse
|
60
|
Benitez J, Boucher ME, Dansin E, Kerjouan M, Bigay-Game I, Pichon E, Thillays F, Falcoz P, Lyubimova S, Oulkhouir Y, Calcagno F, Thiberville L, Clément-Duchêne C, Morin F, Missy P, Thomas P, Maury J, Molina T, Girard N, Besse B. 53P Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
61
|
Bilger G, Girard N, Doubre H, Levra MG, Leprieur EG, Giraud F, Decroisette C, Livartowski A, Massiani MA. 52P Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC): INTEPI, a multicentric retrospective study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
62
|
Morfouace M, Ray-Coquard I, Girard N, Stevovic A, Treilleux I, Meeus P, Aust S, Floquet A, Croce S, Seckl M, Gietema J, Caplin M, delaFouchardiere C, Licitra L, Kapiteijn H, Neumann SP, Idbaih A, Blay J. Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients). Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31155-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
63
|
Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 2020; 31:1320-1335. [PMID: 32745693 PMCID: PMC7836806 DOI: 10.1016/j.annonc.2020.07.010] [Citation(s) in RCA: 204] [Impact Index Per Article: 51.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 07/09/2020] [Accepted: 07/12/2020] [Indexed: 12/14/2022] Open
Abstract
We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed on 28 consensus statements that can be used to overcome many of the clinical and technical areas of uncertainty ranging from diagnosis to therapeutic planning and treatment during the COVID-19 pandemic.
Collapse
|
64
|
Bilger G, Girard N, Giroux-Leprieur E, Giraud F, Friard S, Decroisette C, Levra MG, Livartowski A, Massiani M. 1330P Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1644] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
65
|
Bouée S, Girard N, Moro-Sibilot D, Emery C, Le Lay K, Luciani L, Maritaz C, Chouaid C. Efficacité et coût de la séquence thérapeutique des inhibiteurs de tyrosine kinase (ITK) de l’EGFR de 1ère ou 2e génération suivi d’osimertinib chez les patients atteints d’un cancer bronchique non à petites cellules CBNPC métastatique : TKISeq, une étude française en vie réelle. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.04.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
66
|
Baldacci S, Besse B, Avrillon V, Mennecier B, Dubray-Longeras P, Mazieres J, Descourt R, Duruisseaux M, Quantin X, Doubre H, Monnet I, Moro-Sibilot D, Schneider S, Cousin S, Merle P, Otto J, Langlais A, Morin F, Westeel V, Girard N. 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1617] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
67
|
Girard N, Wermke M, Barlesi F, Kim DW, Ghiringhelli F, Landsteiner H, Jayadeva G, Alt J, Hackanson B. 533MO Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
68
|
Montanez JB, Boucher MÉ, Dansin E, Kerjouan M, Mazieres J, Pichon E, Thillays F, Falcoz P, Roch B, Oulkhouir Y, Calcagno F, Thiberville L, Clément-Duchêne C, Morin F, Missy P, Thomas P, Maury JM, Molina T, Girard N, Besse B. 1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1442] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
69
|
Girard N, Fietkau R, Garassino M, Garrido P, Field J, Peters S, Smit H, Pérol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein A, Diaz Perez I, Sawyer W, Licour M, Christoph D. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
70
|
Girard N, Greillier L, Zalcman G, Cadranel J, Moro-Sibilot D, Mazières J, Audigier-Valette C, Bennouna J, Besse B, Cortot A, Couraud S, Duruisseaux M, Giroux-Leprieur E, Toffart AC, Westeel V, Wislez M. Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. Respir Med Res 2020; 78:100769. [PMID: 32563968 PMCID: PMC7246014 DOI: 10.1016/j.resmer.2020.100769] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 05/11/2020] [Accepted: 05/17/2020] [Indexed: 12/25/2022]
Abstract
The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.
Collapse
|
71
|
Vinches M, Stevovic A, Ray-Coquard I, Treilleux I, Meeus P, Aust S, Floquet A, Croce S, Chalabreysse L, Girard N, Blay JY, Morfouace M. Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
72
|
Girard N, Bouee S, Moro-Sibilot D, Emery C, Lay KL, Luciani L, Maritaz C, Chouaid C. Effectiveness of sequencing TKIs in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): A French national medical-administrative claim database analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
73
|
Girard N, Hackanson B, Wermke M, Barlesi F, Landsteiner H, Jayadeva G, Alt J. Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
74
|
Alcala N, Mangiante L, Le Stang N, Gustafson C, Boyault S, Damiola F, Alcala K, Mazieres J, Blay J, Lantuejoul S, Bueno R, Caux C, Girard N, Mckay J, Foll M, Sallé FG, Fernandez-Cuesta L. MA12.01 Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
75
|
Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Raymond E, Girard N, Sulaiman R, Bresson C, Wunder F, Lee J, Raynaud J, Rubin E, Young B, Lazar V, Felip E, Onn A, Leyland-Jones B, Kurzrock R. Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|